Patents by Inventor Jindan Yu

Jindan Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein
    Patent number: 11981678
    Abstract: Disclosed are compounds that bind to embryonic ectoderm development (EED) protein and proteolysis-targeting chimeric (PROTAC) derivatives thereof that induce degradation of EED. The disclosed compounds may be characterized as substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amine compounds. The disclosed PROTAC derivatives thereof typically include a first targeting moiety that binds to EED (MEED) which may be derived from the disclosed [1,2,4]triazolo[4,3-c]pyrimidin-5-amine compounds that bind to EED. The first targeting moiety typically is linked via a bond or a linker (L) to a second targeting moiety that binds to an E3 ubiquitin ligase (ME3). As such, the disclosed PROTACS may be described as having a formula MEED-L-ME3 or ME3-L-MEED, wherein MEED has a formula of where R2, n, and x are as described herein.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: May 14, 2024
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Jindan Yu
  • Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding
    Patent number: 11919855
    Abstract: Disclosed are substituted pyrrolidones and piperidones which may be utilized as EZH2 targeting agents. The substituted pyrrolidones and piperidones may include substituted 2-pyrrolidones and 2-piperidones. The disclosed pyrrolidones and piperidones may be used in pharmaceutical compositions and methods for treating cell proliferative disorders such as cancer.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 5, 2024
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Jindan Yu
  • SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2
    Publication number: 20230346953
    Abstract: Disclosed are covalent inhibitors of enhancer zeste homolog 2 (EZH2) which may be utilized as EZH2 targeting agents. The disclosed compounds may be characterized as substituted 3-amino-5-phenylbenzamide compounds. The disclosed compounds may be utilized as covalent inhibitors of EZH2 and further may be derivatized to form proteolysis-targeting chimeric molecules (PROTACs) that target EZH2 for degradation. The disclosed compounds and PROTACs may be used in pharmaceutical compositions and methods for treating cell proliferative disorders associated with EZH2 activity, such as cancer.
    Type: Application
    Filed: May 2, 2022
    Publication date: November 2, 2023
    Inventors: Gary E. Schiltz, Jindan Yu
  • SUBSTITUTED [1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-5-AMINE COMPOUNDS AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EMBRYONIC ECTODERM DEVELOPMENT (EED) PROTEIN
    Publication number: 20220372039
    Abstract: Disclosed are compounds that bind to embryonic ectoderm development (EED) protein and proteolysis-targeting chimeric (PROTAC) derivatives thereof that induce degradation of EED. The disclosed compounds may be characterized as substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amine compounds. The disclosed PROTAC derivatives thereof typically include a first targeting moiety that binds to EED (MEED) which may be derived from the disclosed [1,2,4]triazolo [4,3-c]pyrimidin-5-amine compounds that bind to EED. The first targeting moiety typically is linked via a bond or a linker (L) to a second targeting moiety that binds to an E3 ubiquitin ligase (ME3). As such, the disclosed PROTACS may be described as having a formula MEED-L-ME3 or ME3-L-MEED.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 24, 2022
    Inventors: Gary E. Schiltz, Jindan Yu
  • SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING
    Publication number: 20220363633
    Abstract: Disclosed are substituted pyrrolidones and piperidones which may be utilized as EZH2 targeting agents. The substituted pyrrolidones and piperidones may include substituted 2-pyrrolidones and 2-piperidones. The disclosed pyrrolidones and piperidones may be used in pharmaceutical compositions and methods for treating cell proliferative disorders such as cancer.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 17, 2022
    Inventors: Gary E. Schiltz, Jindan Yu
  • ADRB2 cancer markers
    Patent number: 8900819
    Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: December 2, 2014
    Assignee: The Regents of The University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Rohit Mehra
  • Gene fusion targeted therapy
    Patent number: 8143232
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: March 27, 2012
    Assignee: The Regents of the University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Ram Shankar Mani
  • ADRB2 Cancer Markers
    Publication number: 20120046196
    Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.
    Type: Application
    Filed: November 1, 2011
    Publication date: February 23, 2012
    Applicant: The Regents of the University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Rohit Mehra
  • ADRB2 cancer markers
    Patent number: 8058003
    Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: November 15, 2011
    Assignee: The Regents of the University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Rohit Mehra
  • SLIT2 underexpression in metastatic prostate cancer
    Patent number: 7968294
    Abstract: This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to SLIT2 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: June 28, 2011
    Assignee: The Regents of the University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu
  • GENE FUSION TARGETED THERAPY
    Publication number: 20100227910
    Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.
    Type: Application
    Filed: March 3, 2010
    Publication date: September 9, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Ram Shankar Mani
  • SLIT2 CANCER MARKERS
    Publication number: 20100055688
    Abstract: This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to SLIT2 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer.
    Type: Application
    Filed: February 18, 2009
    Publication date: March 4, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY MICHIGAN
    Inventors: Arul M. Chinnaiyan, Jindan Yu
  • ADRB2 CANCER MARKERS
    Publication number: 20090075833
    Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.
    Type: Application
    Filed: January 18, 2008
    Publication date: March 19, 2009
    Applicant: The Regents of the University of Michigan
    Inventors: Arul M. Chinnaiyan, Jindan Yu, Rohit Mehra